Argatroban therapy in heparin-induced thrombocytopenia

Lawrence Rice, Marcie J. Hursting

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Argatroban is a direct thrombin inhibitor approved for anticogulation in heparin-induced thrombocytopenia (HIT; in several countries) and in patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI; in the USA). HIT is a relatively common extreme prothrombotic condition. When HIT is reasonably suspected, an alternative anticoagulant should be promptly initiated. In historical controlled studies, argatroban reduced new thrombosis, mortality from thrombosis and the composite of death, amputation or thrombosis, without increasing bleeding. With intravenous infusion, advantages include short half-life, easy monitoring and elimination primarily by hepatobiliary (rather than renal) means. in patients undergoing PCI, argatroban with or without glycoprotein Ilb/Illa inhibition leads to high rates of procedural success with low bleeding risk. Herein we review argatroban therapy for HIT and for PCI.

Original languageEnglish (US)
Pages (from-to)357-367
Number of pages11
JournalExpert Review of Clinical Pharmacology
Issue number3
StatePublished - Aug 20 2008


  • Argatroban
  • Direct thrombin inhibition
  • Heparin-induced tnrombocytopenia
  • Percutaneous coronary intervention
  • Thrombosis

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Argatroban therapy in heparin-induced thrombocytopenia'. Together they form a unique fingerprint.

Cite this